BioXcel Therapeutics (BTAI) Return on Capital Employed (2018 - 2026)

BioXcel Therapeutics' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 325.86% for Q1 2026.

• In Q1 2026, Return on Capital Employed rose 73792.0% year-over-year to 325.86%; the TTM figure through Mar 2026 stood at 325.86% (up 73792.0% YoY), while the FY2025 annual figure was 410.29%, up 60931.0% from the prior year.
• Return on Capital Employed was 325.86% for Q1 2026 at BioXcel Therapeutics, down from 556.23% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 4316.81% in Q2 2025 to a low of 412.06% in Q1 2025.
• Historically, Return on Capital Employed has averaged 272.95% across 5 years, with a median of 109.23% in 2023.
• The sharpest annual moves came in 2023 and 2025: Return on Capital Employed slumped 20426 bps in 2023, then soared 455212 bps in 2025.
• A 5-year view of Return on Capital Employed shows it stood at 82.96% in 2022, then tumbled by 246 bps to 287.22% in 2023, then slipped by 9 bps to 314.49% in 2024, then surged by 277 bps to 556.23% in 2025, then plunged by 41 bps to 325.86% in 2026.
• The last three Return on Capital Employed figures came in at 325.86% (Q1 2026), 556.23% (Q4 2025), and 2015.99% (Q3 2025), per Business Quant data.